Document is current

Any future updates will be listed below

Phase-III-Daten zum neueren PD-1-Checkpointinhibitor Cemiplimab beim NSCLC

Crossref DOI link: https://doi.org/10.1007/s15004-021-8693-8

Published Online: 2021-06-28

Published Print: 2021-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark